In This Article:
As trade tensions between the U.S. and China show signs of easing, Asian markets have experienced a positive shift, with indices in Japan and China posting gains amid hopes for economic stability. In this context, identifying stocks that may be trading below their intrinsic value can offer investors opportunities to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name | Current Price | Fair Value (Est) | Discount (Est) |
Alexander Marine (TWSE:8478) | NT$145.50 | NT$281.65 | 48.3% |
Newborn Town (SEHK:9911) | HK$8.05 | HK$16.05 | 49.8% |
Members (TSE:2130) | ¥1137.00 | ¥2210.40 | 48.6% |
Rakus (TSE:3923) | ¥2194.50 | ¥4291.28 | 48.9% |
Tongqinglou Catering (SHSE:605108) | CN¥21.32 | CN¥41.17 | 48.2% |
Beijing Zhong Ke San Huan High-Tech (SZSE:000970) | CN¥10.54 | CN¥20.79 | 49.3% |
Wenzhou Yihua Connector (SZSE:002897) | CN¥39.50 | CN¥77.51 | 49% |
Everest Medicines (SEHK:1952) | HK$48.95 | HK$97.21 | 49.6% |
Swire Properties (SEHK:1972) | HK$16.86 | HK$32.76 | 48.5% |
Holtek Semiconductor (TWSE:6202) | NT$41.70 | NT$81.89 | 49.1% |
Let's uncover some gems from our specialized screener.
SK Biopharmaceuticals
Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩8.33 trillion.
Operations: The company's revenue primarily stems from its new drug development segment, generating approximately ₩547.60 million.
Estimated Discount To Fair Value: 36.6%
SK Biopharmaceuticals is trading at ₩106,400, significantly below its estimated fair value of ₩167,884.79. Despite a forecasted annual earnings growth of 7.6%, which lags behind the broader Korean market's 21.5%, the company's revenue is expected to grow robustly at 21.6% per year, outpacing market averages. Additionally, SK Biopharmaceuticals has recently turned profitable and maintains a high forecasted return on equity of 28.6% in three years, suggesting potential for value appreciation based on cash flows.
Newborn Town
Overview: Newborn Town Inc. is an investment holding company that operates in the social networking business globally, with a market cap of HK$10.79 billion.
Operations: The company generates revenue from its Social Networking Business segment, which accounts for CN¥4.63 billion, and its Innovative Business segment, contributing CN¥459.64 million.